RA, No­var­tis back Gen­tiBio's seed round, plans to launch de­vel­op­ment of En­gTreg ther­a­pies

Boston, MA-based start­up Gen­tiBio land­ed a $20 mil­lion seed fund from three in­vestors to dive in­to en­gi­neered reg­u­la­to­ry T cell (En­gTreg) de­vel­op­ment.

Mar­quee in­vestors Or­biMed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER